No Significant Changes to Residual Viremia After Switch to Dolutegravir and Lamivudine in a Randomized Trial

In the ASPIRE trial, antiretroviral therapy (ART) switch to dolutegravir plus lamivudine (DTG+3TC) was comparable to 3-drug ART in maintaining viral suppression by standard viral load assays. We used an ultrasensitive assay to assess whether this switch led to increased residual viremia. At entry, l...

Full description

Saved in:
Bibliographic Details
Published in:Open Forum Infect Dis
Main Authors: Li, Jonathan Z, Sax, Paul E, Marconi, Vincent C, Fajnzylber, Jesse, Berzins, Baiba, Nyaku, Amesika N, Fichtenbaum, Carl J, Wilkin, Timothy, Benson, Constance A, Koletar, Susan L, Lorenzo-Redondo, Ramon, Taiwo, Babafemi O
Format: Artigo
Language:Inglês
Published: Oxford University Press 2019
Subjects:
Brief Report
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6419983/
https://ncbi.nlm.nih.gov/pubmed/30895201
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz056
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items